New Zealand Company HoneyLab today announced that they have licensed seven products to Taro Pharmaceuticals U.S.A., Inc. (“Taro”), a subsidiary of Taro Pharmaceutical Industries, Ltd. (NYSE: Taro). The licence agreement covers the territories of USA, Canada and Israel and includes: Honevo, a patented topical kanuka honey formulation for the treatment of cold sores, rosacea and acne, the bee venom-based cosmetic range Kanu, and Rubeeven, a natural topical treatment for joint and muscle pain.
The agreement terms are confidential but include an up-front fee, payments on milestones and royalties on sales.
HoneyLab is a pharmaceutical company that develops health products from natural sources. Founder Dr Shaun Holt said that “this deal is a huge milestone for the company. It validates our business model of applying a pharmaceutical approach to natural products by undertaking extensive R&D, developing strong intellectual property, and then finding partners in overseas territories who license the products”.
HoneyLab CEO, Anthony Lawler added, “we think that Taro, with its strong distribution networks and marketing expertise is the perfect partner to launch our products in these territories”.
HoneyLab has a large pipeline of novel, natural products at various stages of development.
About HoneyLab New Zealand
- A New Zealand pharmaceutical company developing health products from natural sources
- Has undertaken the world’s largest programme of medical honey research
- Platforms of clinical research include dermatology, pain, infection and nutrition
14th July 2020
Contact: Anthony Lawler, phone +64 21 577 384, email@example.com